Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
TF

NASDAQ · TFFP

TFF Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.07

Down-$0.10 (-60.05%)

Updated Aug 15, 2026, 3:09 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
288.8K
P/E ratio
-0.04
Dividend yield
0.00%
52-week range
— – —
Volume
11.02M
Avg. volume
1.69M

Price performance

TFFP price history

1M range · 0 trading sessions · Daily adjusted prices

TFFP does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest TFFP news

The latest Smart Investors Daily articles mentioning TFFP.

Stock researchCompany · Overview

TFFP research

Overview

Company profile and research snapshot.

Company profile

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$30.60
Implied upside
—
Analysts
7
TFFP recent ratings
DateFirmRatingTarget
Mar 28, 2024Roth MKMBuy—
May 25, 2023HC Wainwright & Co.Buy—
Mar 22, 2023JonesTradingBuy—
Mar 17, 2023HC Wainwright & Co.Buy—
Mar 29, 2022B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Sep 10, 2024

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals announced positive preclinical data for its bivalent universal influenza vaccine candidates, which induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains. The company is working with Cleveland Clinic to advance the vaccine candidate towards IND and early clinical trials.

GlobeNewswire Inc. · May 1, 2024

TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering

FORT WORTH, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share (or per common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $2.75 per share, are exercisable immediately for a period of five years from the date of issuance.

GlobeNewswire Inc. · Apr 30, 2024

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the pricing of a public offering of an aggregate of 1,665,219 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,665,219 shares of common stock at a combined public offering price of $2.875 per share (or per common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $2.75 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 1, 2024, subject to the satisfaction of customary closing conditions.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By